Mirna Therapeutics, Inc. (NASDAQ:MIRN) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
press release announcing its financial results for the fourth
quarter and year ended December 31, 2016. The press release is
attached hereto as Exhibit 99.1.
Exhibit 99.1 attached hereto shall not be deemed filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that Section or Sections 11 and 12(a)(2) of the
Securities Act of 1933, as amended (the Securities Act), or
incorporated by reference in any filing of Mirna under the
Securities Act or the Exchange Act, whether made before or after
the date hereof, regardless of any general incorporation language
in such filing.
|
Exhibit
No.
|
Description
|
|
|
99.1
|
Press release dated March 14, 2017.
|
About Mirna Therapeutics, Inc. (NASDAQ:MIRN)
Mirna Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response. This approach is known as microRNA replacement therapy. Its lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34) encapsulated in a liposomal nanoparticle formulation, has demonstrated clinical proof of concept as a single agent in its ongoing Phase I clinical trial. The Company’s RNA molecules function as natural microRNAs when they enter human cells. These RNA molecules, which it calls microRNA mimics, may be used to replace those tumor suppressor microRNAs that are lost, or under expressed, in cancer cells. Its other preclinical product candidates include miR-215, miR-101, miR-16 and let-7. Mirna Therapeutics, Inc. (NASDAQ:MIRN) Recent Trading Information
Mirna Therapeutics, Inc. (NASDAQ:MIRN) closed its last trading session down -0.01 at 2.28 with 78,350 shares trading hands.
